Details for: BREVICON
Company: PFIZER CANADA ULC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02187086 | BREVICON 0.5/35 TABLETS (21-DAY PACK) | ETHINYL ESTRADIOL; NORETHINDRONE | 0.035 MG; 0.5 MG | TABLET | ORAL |
| 02187094 | BREVICON 0.5/35 TABLETS (28-DAY PACK) | ETHINYL ESTRADIOL; NORETHINDRONE | .035 MG; .5 MG | TABLET | ORAL |
| 02189054 | BREVICON 1/35 TABLETS (21-DAY PACK) | NORETHINDRONE; ETHINYL ESTRADIOL | 1 MG; 0.035 MG | TABLET | ORAL |
| 02189062 | BREVICON 1/35 TABLETS (28-DAY PACK) | NORETHINDRONE; ETHINYL ESTRADIOL | 1 MG; 0.035 MG | TABLET | ORAL |
Summary Reports
Summary Safety Review - Hormone Replacement Therapy (Estrogenic and Progestogenic Agents) and Selective Estrogen Receptor Modulators (SERMs) - Assessing the Potential Risk of Ovarian Cancer
Summary Safety Review - Combined Hormonal Birth Control Products - Evaluating effectiveness when used by women who are obese
Summary Safety Review - Hormonal Birth Control Products (excluding Emergency Birth Control Products) - Assessing the Potential Risk of Suicidal Thoughts and Behaviours (suicidality)
Summary Safety Review - Combined Hormonal Birth Control Products - Evaluating effectiveness when used by women who are obese
Summary Safety Review - Hormonal Birth Control Products (excluding Emergency Birth Control Products) - Assessing the Potential Risk of Suicidal Thoughts and Behaviours (suicidality)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.